MelissaHe Ph.D.


San Diego + 1.858.314.1154

Dr. Melissa He prosecutes patents and manages patent portfolios worldwide in the areas of pharmaceuticals, biotechnology, chemistry, and traditional Chinese medicine (TCM). She provides clients with a broad range of services, including U.S. and foreign patent portfolio development and management, due diligence investigation, patentability and validity assessments, freedom-to-operate analysis, and patent strategy counseling.

Melissa also has experience in patent litigation and post-grant proceedings, including inter partes review (IPR) before the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO).

Her representative clients include AbbVie and Celgene, as well as other start-up companies, established companies, academic institutions, and investment firms.

Prior to joining Jones Day, Melissa was an IP and life sciences analyst for more than three years at an international law firm and worked as a scientist for more than 10 years. During her post-doctoral fellowship at the National Institutes of Health (NIH), she researched discovery (or repurposing) and development of pharmaceutical candidates treating infectious diseases. Melissa is a co-inventor of patent applications and the first author of several peer-reviewed scientific publications in journals including Science Translational Medicine and Journal of Medicinal Chemistry. Her publications have been featured in "Research Highlights" in Nature Reviews Drug Discovery and Nature Reviews Gastroenterology & Hematology and selected for American Chemical Society's ACS Editors' Choice. Her research also has been spotlighted in NIH Research Matters, Yahoo News, and TIME Health.


  • AbbVie develops patent portfolio related to adalimumab formulationsJones Day is representing AbbVie Inc. in connection with the development of global patent portfolios related to formulations for AbbVie's antibody adalimumab, marketed as HUMIRA®.
  • Celgene acquired by Bristol-Myers Squibb for approximately $74 billionJones Day advised Celgene Corporation (NASDAQ: CELG) in connection with the intellectual property and technology transactions aspects of its cash-and-stock merger with Bristol-Myers Squibb (NYSE: BMY) which has an equity value of approximately $74 billion.